

Hematological Profile of Untreated or Ionizing Radiation-Exposed Cyclooxygenase-2-Deficient Mice

Michal Hofer¹, Zuzana Hoferová¹, Ladislav Dušek², Karel Souček^{3,4,5}, Artiom Gruzdev⁶

¹Department of Molecular Cytology and Cytometry, Institute of Biophysics of the CAS, v.v.i., Brno, Czech Republic

²Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

³Department of Cytokinetics, Institute of Biophysics of the CAS, v.v.i Brno, Czech Republic

⁴International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic

⁵Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic

⁶Laboratory of Respiratory Biology, Division of Intramural Research, NIEHS/NIH, Research Triangle Park, NC 27709, USA

Corresponding Author: Michal Hofer, Department of Molecular Cytology and Cytometry, Institute of Biophysics of the CAS, v.v.i. , Královopolská 135, CZ-61265 Brno, Czech Republic, telephone: +420/541517171, fax: +420/541211293, e-mail: hofer@ibp.cz

Short Title: Hematopoiesis in Cyclooxygenase-2-Deficient Mice

Summary

We investigated hematopoiesis in untreated and ionizing radiation-exposed cyclooxygenase-2-deficient (COX-2 KO) mice. We performed a complex hematological analysis of 16 parameters in untreated COX-2 KO male mice or COX-2 KO male mice irradiated with the dose of 4 Gy of γ -rays and their wildtype littermates. At baseline, hematopoiesis was increased in COX-2-deficient mice, but attenuated by irradiation in COX-2-deficient mice compared to wildtype. To conclude, the anti-inflammatory action of the COX-2 genetic disruption plays a positive role in hematopoiesis under basal conditions but is detrimental following radiation exposure.

Key words

Cyclooxygenase-2; COX-2 knock-out mice; hematopoiesis; ionizing radiation; post-irradiation inflammation

Introduction

Previously, we tested hematological effects of meloxicam, an anti-inflammatory drug and a selective COX-2 inhibitor (Carrabba *et al.* 1995), and we observed stimulation of hematopoiesis and improved post-irradiation survival in meloxicam-treated animals (Hofer *et al.* 2006, 2008a, 2008b, 2011). In this study, we used cyclooxygenase-2-deficient (COX-2 KO) mice for hematological examinations under basal conditions and following radiation-induced myelosuppression. Loss of COX-2 activity in the COX-2 KO mice is chronic, absolute, and selective, while pharmacological COX-2 inhibition is acute, potentially not absolute, and may result in non-selective co-inhibition of cyclooxygenase-1 (Patrignani and Patrono 2015). This is why an analysis of hematopoiesis in COX-2 KO mice can give new knowledge on the regulatory role of COX-2 in the hematopoietic system.

Methods

Mice: 10-week-old male COX-2-deficient and wildtype littermates on a 129B6F1 genetic background were used (Morham *et al.* 1995). The use and treatment of the animals followed the European Community Guidelines. The experiments were approved by the Institute's Ethical Committee.

Irradiation: The mice were whole-body irradiated at a dose rate of 0.34 Gy/min using a γ -ray source (^{60}Co , Chisostat, Chirana, Prague, Czech Republic).

Hematological methods: The animals were anesthetized with an i.p. injection of a Narkamon /Rometar (Spofa, Prague, Czech Republic). The peripheral blood was collected by cardiac puncture. The values of total leukocytes, neutrophils, lymphocytes, erythrocytes, and platelets per 1 μ l of the peripheral blood, blood hemoglobin level, hematocrit, mean erythrocyte volume, mean erythrocyte hemoglobin, mean erythrocyte hemoglobin concentration, mean platelet volume, and plateletcrit were determined by an Auto Hematology Analyzer Mindray 5300Vet (Shenzen, China). The numbers of femoral nucleated cells were determined by a Coulter Counter (Model ZF, Coulter Electronics, Luton, UK).

Granulocyte-macrophage and erythroid colony-forming cells (GM-CFC and BFU-E, respectively), were assessed using MethoCult M3001 and MethoCult SF M3436, respectively (Stem Cell Technologies, Vancouver, Canada) (for details, see Hofer *et al.* 2015).

Statistics: The experiments were performed twice and their results were combined. Statistical significance of the differences between WT and COX-2 KO mice were tested by Mann-Whitney U test.

Results

The values of 16 parameters of the peripheral blood, bone marrow and spleen in untreated COX-2 KO (cyclooxygenase-2-deficient) mice or COX-2 KO mice irradiated with a sublethal dose of 4 Gy of γ -rays, and in WT (wild-type) mice are shown in Table 1.

It follows from the findings that the genetic disruption of COX-2 has different effects in the hematopoietic system in basal conditions and following exposure to a sublethal radiation dose. In untreated mice, 4 parameters were significantly higher and none were significantly lower in COX-2 KO mice compared to WT mice. In irradiated mice, 4 parameters were significantly lower and of none were significantly higher in COX-2 KO mice compared to WT mice (Table 1).

In 14 out of the 16 hematological parameters shown, the values in COX-2 KO mice could be expressed as per cent of those in the WT mice in both the untreated and irradiated animals; blood neutrophils and lymphocytes could not be determined in irradiated mice. In 11 out of 14 parameters accessible in this way, this value in irradiated mice was lower compared to that in the untreated ones (Table 1).

Discussion

Radiation-induced inflammation is a long known and widely studied phenomenon (Schaue *et al.* 2015). The bone marrow radiation syndrome, which has been induced in this study by the dose of 4 Gy of γ -rays, is naturally accompanied by manifestations of an acute inflammation (Casey-Sawicki *et al.* 2014). This communication is the first attempt to use COX-2 KO mice for the evaluation of the effects of COX-2 genetic disruption on hematopoiesis under both basal conditions and following a sublethal radiation exposure. The life-long loss of the COX-2 activity in the COX-2 KO mice should produce a permanent anti-inflammatory effect.

These initial results on this topic do not allow for detailed analyses and conclusions. However, a basic inference can be made from the findings obtained: whereas in untreated COX-2 KO mice, the anti-inflammatory effects of chronic COX-2-deficiency positively affect hematopoiesis, the opposite is true in irradiated COX-2-deficient mice. As concerns the post-irradiation conditions, the findings in this study differ from those previously obtained following acute pharmacological COX-2 inhibition (Hofer *et al.* 2006, 2008a, 2008b, 2011) where stimulation of hematopoiesis was observed following administration of a selective COX-2 inhibitor.

The observed decline in the numbers of hematopoietic progenitor cells in the bone marrow of the irradiated COX-2 KO mice suggests that also numbers of the peripheral blood neutrophils, which are important for the evaluation of the inflammatory status in these

animals, should be decreased in the irradiated COX-2-deficient mice. Due to the very low levels of the total blood leukocytes in the irradiated mice, not enabling to determine the neutrophil numbers (see the Legend to Tab. 1), their values, as well as the values of their subpopulations, including neutrophils, will be determined by an other method, e.g. by flow-cytometry, in the subsequent study.

To conclude, it seems that radiation-induced inflammation results in stimulation of hematopoiesis in the irradiated mice; consequently, the chronic anti-inflammatory effects of COX-2 genetic disruption in the COX-2 KO mice cause hematopoiesis-suppressing action in the post-irradiation conditions. Further studies are needed to obtain more data on hematopoiesis in radiation-exposed COX-2 KO mice and on how hematopoietic processes in these mice are reflected in their post-irradiation survival. The results of the survival studies should also show whether the expected radiation damage to the gastrointestinal tissues evoked with high radiation doses can be influenced in the COX-2 KO mice in which the production of cyclooxygenase-1, important for the gastrointestinal tract, should be preserved.

Acknowledgment: This work was supported by project no. LQ1605 from the National Program of Sustainability II (MEYS CR), by the European Union - project ICRC-ERA-HumanBridge (No. 316345), and from the Czech Science Foundation (grant No. 16-1245S).

References

- CARABBA M, PARESC E, ANGELINI M, GALANTI A, MARINI MG, CIGARINI P: A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: A single blind, randomized, multicentre study. *Curr. Med. Res. Opin.* **13**: 343-355, 1995.
- CASEY-SAWICKI K, ZHANG M, KIM S, ZHANG A, ZHANG SB, ZHANG ZH, SINGH R, YANG SM, SWARTS S, VIDYASAGAR S, ZHANG LR, ZHANG AG, OKUNIEFF P: A basic fibroblast growth factor analog for protection and mitigation against acute radiation syndromes. *Health Phys.* **106**: 704-712, 2014.
- HOFER M, POSPÍŠIL M, DUŠEK L, HOFEROVÁ Z, KOMŮRKOVÁ D: Hematopoiesis in 5-fluorouracil-treated adenosine A₃ receptor knock-out mice. *Physiol. Res.* **64**: 255-262, 2015.
- HOFER M, POSPÍŠIL M, DUŠEK L, HOFEROVÁ Z, WEITEROVÁ L: A single dose of an inhibitor of cyclooxygenase 2, meloxicam, administered shortly after irradiation, increases survival of lethally irradiated mice. *Radiat. Res.* **176**: 269-272, 2011.
- HOFER M, POSPÍŠIL M, HOLÁ J, VACEK A, ŠTREITOVÁ D, ZNOJIL V: Inhibition of cyclooxygenase 2 in mice increases production of G-CSF and induces radioprotection. *Radiat. Res.* **170**: 566-571, 2008a.
- HOFER M, POSPÍŠIL M, ZNOJIL V, HOLÁ J, VACEK A, ŠTREITOVÁ D: Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be usable as an auxiliary means in G-CSF therapy. *Physiol. Res.* **57**: 307-310, 2008b.
- HOFER M, POSPÍŠIL M, ZNOJIL V, HOLÁ J, VACEK A, WEITEROVÁ L, ŠTREITOVÁ D, KOZUBÍK A: Meloxicam, a cyclooxygenase-2 inhibitor, supports hematopoietic recovery in gamma-irradiated mice. *Radiat. Res.* **166**: 556-560, 2006.

MORHAM SG, LANGENBACH R, LOFTIN CD, TIANO HF, VOULOUMANOS N, JENNETTE JC, MAHLER JF, KLUCKMAN KD, LEDFORD A, LEE CA, SMITHIES O: Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. *Cell* **83**: 473-482, 1995.

PATRIGNANI P, PATRONO C: Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. *Biochim. Biophys. Acta* **1851**: 422-432, 2015.

SCHAUE D, MICEWICZ ED, RATIKAN JA, XIE MW, CHENG GH, MCBRIDE WH: Radiation and inflammation. *Semin. Radiat. Oncol.* **25**: 4-10, 2015.

Table 1. Values of hematological parameters in untreated and 4 Gy-irradiated mice

Parameter	Untreated WT mice (n=7)	Untreated COX-2 KO mice (n=7)	4 Gy-irradiated WT mice (n=8)	4 Gy-irradiated COX-2 KO mice (N=7)
Blood leukocyte count ($\times 10^9/l$) [@]	3.01 \pm 0.40	4.66 \pm 0.70 (155%)	0.36 \pm 0.02	0.47 \pm 0.05 (131%)
Blood neutrophil count ($\times 10^9/l$)	0.71 \pm 0.15	2.33 \pm 0.59 #	ND	ND
Blood lymphocyte count ($\times 10^9/l$)	2.24 \pm 0.35	2.07 \pm 0.11	ND	ND
Blood erythrocyte count ($\times 10^{12}/l$) [@]	9.10 \pm 0.13	8.89 \pm 0.45 (98%)	8.07 \pm 0.14	7.70 \pm 0.27 (95%)
Blood hemoglobin level (HGB) (g/l) [@]	137.3 \pm 1.2	132.0 \pm 5.7 (96%)	123.7 \pm 1.4	116.4 \pm 3.8 (94%)
Hematocrit (HCT) (%) [@]	45.6 \pm 0.4	43.9 \pm 1.7 (96%)	40.5 \pm 0.6	38.1 \pm 1.2 (94%)
Mean erythrocyte volume (MCV) (fl) [@]	50.9 \pm 0.2	50.5 \pm 1.3 (99%)	50.8 \pm 0.2	49.4 \pm 0.4 ** (97%)
Mean erythrocyte hemoglobin (MCH) (pg) [@]	15.3 \pm 0.1	15.1 \pm 0.3 (99%)	15.5 \pm 0.1	15.1 \pm 0.1 ** (97%)
Mean erythrocyte hemoglobin concentration (MCHC) (g/l)	301.2 \pm 1.7	300.1 \pm 1.8 (100%)	305.4 \pm 1.3	305.8 \pm 0.9 (100%)

Table 1. – continued. Values of hematological parameters in untreated and 4 Gy-irradiated mice

Parameter	Untreated WT mice (n=7)	Untreated COX-2 KO mice (n=7)	4 Gy-irradiated WT mice (n=8)	4 Gy-irradiated COX-2 KO mice (n=7)
Blood platelet count (x 10 ⁹ /l)	897.4 ± 37.7	1008.2 ± 57.4 (112%)	906.2 ± 55.1	1038.0 ± 109.0 (114%)
Mean platelet volume (fl) [@]	4.53 ± 0.04	4.70 ± 0.02 ### (104%)	4.51 ± 0.04	4.52 ± 0.04 (100%)
Plateletcrit (%)	0.41 ± 0.02	0.47 ± 0.03 (115%)	0.41 ± 0.02	0.47 ± 0.05 (115%)
¹ Femoral bone marrow cellularity / g body weight (x 10 ³) [@]	0.95 ± 0.02	1.00 ± 0.02 (105%)	0.27 ± 0.01	0.21 ± 0.01 ** (78%)
¹ GM-CFC /femur / g body weight [@]	495.9 ± 13.7	565.2 ± 18.78 ## (114%)	77.0 ± 8.5	58.8 ± 5.7 (76%)
¹ BFU-E/femur / g body weight [@]	505.0 ± 33.9	579.1 ± 20.2 (115%)	60.1 ± 3.8	40.3 ± 6.3 * (67%)
¹ Spleen weight / g body weight (g) [@]	2.62 ± 0.19	5.53 ± 1.10 ### (211%)	1.59 ± 0.11	1.95 ± 0.17 (123%)

Legend to Table 1. The results are presented as arithmetic means ± standard errors of the means (SEM). n = numbers of mice. ¹ - considering the differences in the average body weight between the groups of mice studied (results not shown), the values of the bone marrow parameters and that of the spleen weight were expressed as per 1 g of body weight. ND = not done (the analyzer used allows to determine numbers of neutrophils and lymphocytes only when the total leukocyte number exceeds the value of 0.5x10⁹/l). #, ##, ### - value in COX-2 KO mice is statistically significantly higher (P≤0.05, P≤0.01, P≤0.001, respectively) than that in the corresponding WT counterparts. *, ** - value in COX-2 KO mice is statistically significantly lower (P≤0.05, P≤0.01, respectively) than that in the corresponding WT counterparts. [@] - value of the pertinent parameter in COX-2 KO mice, expressed as per cent of that in respective WT mice, is lower in irradiated animals.